Figures computed from official regulatory filings — .
Analysttarget 7.13 USD (+385%) · consensus 5/5 · 4 buy · 0 hold · 0 sell
Ownershipinsiders 3.6% · institutions 20.38% · short 1.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for RenovoRx, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
36 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Spiegel Robert J. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| RYAN UNA Strack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Marton Laurencetrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Macfarlane Kirsten Angela | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| VOLL MARK | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| RYAN UNA Strack record | Other | $25K | SEC | ||
| RYAN UNA Strack record | Other | $26.3K | SEC | ||
| RYAN UNA Strack record | Other | $25K | SEC | ||
| RYAN UNA Strack record | Other | $200.2K | Unusual size | SEC | |
| VOLL MARK | Buy | $19.7K | conv 69Cluster | SEC | |
| Gentry Leesa | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| VOLL MARK | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Bagai Shauntrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Agah Ramtintrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| VOLL MARK | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC | ||
| Bagai Shauntrack record | Buy | n/a (No price was disclosed in the filing) | conv 47Cluster | SEC | |
| VOLL MARK | BuyD (derivative) | n/a (No price was disclosed in the filing) | ClusterFirst in 12mo | SEC | |
| Bagai Shauntrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | Cluster | SEC | |
| Marton Laurencetrack record | Buy | n/a (No price was disclosed in the filing) | conv 62Cluster | SEC | |
| Marton Laurencetrack record | BuyD (derivative) | n/a (No price was disclosed in the filing) | Cluster | SEC | |
| VOLL MARK | Buy | n/a (No price was disclosed in the filing) | conv 83ClusterFirst in 12mo | SEC | |
| Agah Ramtintrack record | Buy | $10K | conv 26 | SEC | |
| Agah Ramtintrack record | Buy | $8.4K | conv 28 | SEC | |
| Agah Ramtintrack record | Buy | $170.2 | conv 28Unusual size | SEC | |
| Bagai Shauntrack record | Buy | $4.5K | conv 31 | SEC |